Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …

Skin cancer is a global threat to the healthcare system and is estimated to incline
tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is …